Literature DB >> 33567245

The Pre-Exposure Prophylaxis Cascade in At-Risk Transgender Men Who Have Sex with Men in the United States.

Sari L Reisner1,2,3,4, Chiara S Moore1, Andrew Asquith1, Dana J Pardee1, Kenneth H Mayer1,3,5,6.   

Abstract

Purpose: This analysis was designed to characterize the pre-exposure prophylaxis (PrEP) cascade in a U.S. national sample of transgender men and trans masculine adults who have sex with cisgender men (trans MSM) at-risk for HIV acquisition.
Methods: From November to December 2017, 843 HIV-negative trans MSM self-reporting past-6-month receptive sex with a cisgender man were recruited via peer referrals, dating apps, listservs, and social media. A computer-assisted self-interview assessed demographics, health care, and the PrEP cascade. Descriptive statistics and multivariable regression models evaluated factors associated with PrEP uptake and persistence.
Results: Mean age was 28.1 years (standard deviation = 7.1); 4.8% were Black, 21.7% Latinx, and 25.6% another race/ethnicity. A total of 84.1% had heard of PrEP, with 67.3% reporting interest. More than half (55.2%) were PrEP indicated, of which 50.8% were PrEP naive. Approximately 1/4 (28.0%) reported PrEP use, of which 65.3% were PrEP persistent. PrEP modality preferences were injectable (51.2%), daily oral pill (22.1%), and anal gel/lube (14.6%). Reasons for PrEP noninterest were no HIV risk (68.5%), cost (24.2%), and side effects (20.1%). Surgical gender affirmation, no health care discrimination, and social media as a primary health information source were associated with increased odds of PrEP uptake and persistence (all p < 0.05). PrEP adherence difficulties were reported by 52.6%, due to busy/inconsistent schedule (53.1%), side effects (27.4%), and too many medical visits (11.6%).
Conclusion: PrEP uptake was modest among the trans MSM sampled, given prevalent HIV risk behaviors. The limited PrEP uptake in at-risk trans MSM suggests the need to develop culturally tailored community education and interventions.

Entities:  

Keywords:  HIV prevention; MSM; PrEP; transgender

Year:  2021        PMID: 33567245     DOI: 10.1089/lgbt.2020.0232

Source DB:  PubMed          Journal:  LGBT Health        ISSN: 2325-8292            Impact factor:   4.151


  10 in total

1.  An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.

Authors:  Ian M McGowan; Ratiya Pamela Kunjara Na Ayudhya; Rhonda M Brand; Mark A Marzinke; Craig W Hendrix; Sherri Johnson; Jeanna Piper; Timothy H Holtz; Marcel E Curlin; Anupong Chitwarakorn; Boonyos Raengsakulrach; Gustavo Doncel; Jill L Schwartz; James F Rooney; Ross D Cranston
Journal:  AIDS Res Hum Retroviruses       Date:  2021-10-29       Impact factor: 1.723

2.  What Predicts a Clinical Discussion About PrEP? Results From Analysis of a U.S. National Cohort of HIV-Vulnerable Sexual and Gender Minorities.

Authors:  Pedro B Carneiro; Victoria Frye; Chloe Mirzayi; Viraj Patel; David Lounsbury; Terry T-K Huang; Nasim Sabounchi; Christian Grov
Journal:  AIDS Educ Prev       Date:  2022-06

3.  Geographic Variation in HIV Testing Among Transgender and Nonbinary Adults in the United States.

Authors:  Diana M Tordoff; Sahar Zangeneh; Christine M Khosropour; Sara N Glick; Raymond Scott McClelland; Dobromir Dimitrov; Sari Reisner; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-15       Impact factor: 3.771

4.  PrEP Use and Adherence Among Transgender Patients.

Authors:  Jae Downing; Kimberly Yee; Jae M Sevelius
Journal:  AIDS Behav       Date:  2021-10-13

5.  Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence.

Authors:  Maria Pyra; Russell Brewer; Laura Rusie; Jeanelle Kline; India Willis; John Schneider
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

6.  Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.

Authors:  Karine Dubé; John Kanazawa; Chadwick Campbell; Cheriko A Boone; Allysha C Maragh-Bass; Danielle M Campbell; Moisés Agosto-Rosario; Jamila K Stockman; Dázon Dixon Diallo; Tonia Poteat; Mallory Johnson; Parya Saberi; John A Sauceda
Journal:  AIDS Res Hum Retroviruses       Date:  2021-05-31       Impact factor: 2.205

7.  Close, But Not Quite: One in Twenty Trans and Gender Diverse Individuals Assigned Female at Birth Are Being Prescribed the Wrong Kind of PrEP.

Authors:  Christian Grov; Viraj V Patel; Alexa B D'Angelo; Fatima Zohra; Max Nicoli Appenroth
Journal:  J Acquir Immune Defic Syndr       Date:  2021-10-01       Impact factor: 3.771

8.  HIV Pre-exposure Prophylaxis Continuum of Care Among Transgender Individuals in an Integrated Health care System.

Authors:  J Carlo Hojilla; Leo B Hurley; Julia L Marcus; Derek D Satre; Michael J Silverberg; Eve F Zaritsky; Darios Getahun; Michael Goodman; Jonathan E Volk
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-01       Impact factor: 3.771

9.  Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California.

Authors:  Jae M Sevelius; David V Glidden; Madeline Deutsch; Layla Welborn; Alejandro Contreras; Arianna Salinas; Luz Venegas; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2021-12-15       Impact factor: 3.771

10.  HIV prevalence among transmasculine individuals at a New York City Community Health Centre: a cross-sectional study.

Authors:  Asa E Radix; Elaine L Larson; Alexander B Harris; Mary Ann Chiasson
Journal:  J Int AIDS Soc       Date:  2022-10       Impact factor: 6.707

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.